In situ hybridization

Oligonucleotides Global Markets Report 2024: Historical Market Revenue Data from 2020 to 2022, Estimates for 2023, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, General Health, Health, Genetics, Pharmaceutical, Diagnosis, Cytomegalovirus retinitis, PCR, Eurofins Scientific, Thermo Fisher Scientific, Disease, Oligonucleotide, CMV, ESG, Integration, Estimation, Research, RNA, DNA, Cancer, Competition, Infection, Agilent Technologies, Hepatitis, Spinal cord, In situ hybridization, Therapy, USD, FDA, Liver, Polymerase chain reaction, Fine chemical

The Global Oligonucleotides Market was valued at USD 7 Billion in 2023, and is expected to reach USD 11.7 Billion by 2028, rising at a CAGR of 11.00%.

Key Points: 
  • The Global Oligonucleotides Market was valued at USD 7 Billion in 2023, and is expected to reach USD 11.7 Billion by 2028, rising at a CAGR of 11.00%.
  • This report covers the worldwide market for oligonucleotide synthesis, which consists of four main product types: oligonucleotide drugs, synthesized oligos, equipment and reagents, and services.
  • Based on application, the market for oligonucleotide synthesis is divided into research diagnostics and therapeutics.
  • The report also covers approved drugs, the oligonucleotide synthesis process, innovative research, opportunities within the market and profiles of leading companies in the oligonucleotide synthesis industry.

STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, FDA, Medical Devices, Clinical Trials, Pharmaceutical, Biotechnology, De novo, Stemcell Technologies, Plasma, In situ hybridization, Medicine, Cell, Bone marrow, Partnership, Risk, Patient, Fluorescence, Sale, Classification, Multiple myeloma, DSM-IV codes, B cell, IVD, National Comprehensive Cancer Network, American College, European, FISH, Cancer, CD138, Multimedia, Food, Medical device

STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.

Key Points: 
  • STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.
  • View the full release here: https://www.businesswire.com/news/home/20240326396951/en/
    STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit is now classified by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.
  • (Photo: Business Wire)
    The kit can be used to enrich plasma cells expressing the CD138 marker (CD138+ cells) from patient bone marrow samples.
  • The EasySep™ Human Bone Marrow CD138 Positive Selection Kit will be available for sale in the United States, the European Union, Canada, and the United Kingdom.

Enhanced Multiplex IHC Technology for Precision Oncology, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, February 6, 2024
TME, Tumor microenvironment, Biomarker, Doctor of Philosophy, In situ hybridization, Drug development, Complex, RNA, Protein, ISH, Medical imaging

TORONTO, Feb. 6, 2024 /PRNewswire-PRWeb/ -- Unlock the potential of cutting-edge technology in oncology research. Dive into the latest breakthroughs in multiplex immunohistochemistry (IHC) during this upcoming webinar about Veracyte's Brightplex® technology, a prominent example of multiplex IHC advancements. This webinar will explore innovative features that elevate the capabilities of this technology, providing a deeper understanding of not only the tumor microenvironment (TME) but also the critical imperative for biomarkers in the context of clinical trials.

Key Points: 
  • In this free webinar, learn the latest advancements surrounding Veracyte's multiplex immunohistochemistry (IHC) assay.
  • Attendees will discover how coupling IHC and in situ hybridization (ISH) can help in cancer research and drug development.
  • Dive into the latest breakthroughs in multiplex immunohistochemistry (IHC) during this upcoming webinar about Veracyte 's Brightplex® technology, a prominent example of multiplex IHC advancements.
  • Brightplex new features incorporate in situ hybridization (ISH) probes for the detection of RNA transcripts alongside traditional multiplex IHC biomarkers.

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Retrieved on: 
Tuesday, January 30, 2024
SAN, Breast, University, International, MD Anderson Cancer Center, FACMG, FDA, VAF, Bone marrow, SVS, Cytogenetics, Genome, LRS, OGM, University of Toronto, TNBC, Pressure, Biomarker, PARP, Quality control, Karyotype, HRD, Saint John Regional Hospital, T-ALL, CRISPR, Curie Institute, Triple-negative breast cancer, In situ hybridization, FISH, Frog, Genomics, Hospital, HRP, Patient, Marfan syndrome, Fluorescence, NIST, DSM-IV codes, Doctor of Philosophy, Cancer, Multiple myeloma, Workflow, Gene editing, Research, KT, Cell, Down syndrome, NGS, Vaccine

During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.
  • OGM is helping to unravel persistent, complex mysteries in genetic disease that impact people, even in more common disorders like Down syndrome and Marfan syndrome.
  • OGM has the potential to meet the key requirements of the cell and gene therapy community.
  • “I would encourage anyone who was unable to attend live to login, view these presentations and see how bright the future of cytogenetics is with OGM.”

Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing

Retrieved on: 
Wednesday, January 24, 2024
SAN, Standard of care, Fluorescence, University of Rochester, Test management, University, SVS, FISH, Genomics, DSM-IV codes, In situ hybridization, IRB, SOC, Karyotype, CMA, KT, Columbia University, OGM, Clinical trial, Institutional review board, Data, Diagnosis, Medical device

This publication reports on the prenatal genetic disease clinical trial program to evaluate OGM as an alternative to SOC workflows.

Key Points: 
  • This publication reports on the prenatal genetic disease clinical trial program to evaluate OGM as an alternative to SOC workflows.
  • This second interim readout is designed to evaluate endpoints connected to analytical performance using an expanded dataset in key areas of technical performance and clinical utility of OGM.
  • The study is an Institutional Review Board (IRB)-approved, multicenter, double-blinded trial with samples from 219 unique retrospective (57) and prospective (162) clinical research subjects.
  • All samples had been previously tested with traditional methods including karyotyping (KT), fluorescence in situ hybridization (FISH) and chromosomal microarray (CMA).

New Tool Reveals Gene Behavior in Bacteria

Retrieved on: 
Wednesday, January 24, 2024
Death, ECG, DNA replication, Alfred P. Sloan Foundation, TRIPS Agreement, Heart, DNA, Ralph, Champaign–Urbana metropolitan area, Publishing, Gene, University, Medicine, Genetics, Environment, Tick, In situ hybridization, Bacteria, NYU, Human, Cell cycle, Disease, NYU Langone Health, Protein, Nature, Doctor of Philosophy, Genome, National Institutes of Health, Messenger, Gene expression, Bangladesh Technical Education Board, Pathogenic bacteria, TRIP, Cell, Vaccine

This is due in part to the ability of bacteria to switch genes on and off as they sense environmental changes, including the presence of drugs.

Key Points: 
  • This is due in part to the ability of bacteria to switch genes on and off as they sense environmental changes, including the presence of drugs.
  • According to the study authors, organisms from bacteria to humans grow as their cells multiply by dividing, with each cell becoming two.
  • Specifically, the research team found that when DNA polymerase arrives at any specific gene, it disrupts the transcription in a way that reveals the state of that gene's regulatory status.
  • Ultimately, they believe that improvements in technology will enable them to dive ever deeper into gene behaviors in different bacterial species.

Biocare Medical and Molecular Instruments Partner to Revolutionize Automated Bioimaging Through ONCORE Pro X and HCR™ RNA-ISH Assays

Retrieved on: 
Friday, January 5, 2024
RNA, In situ hybridization, Partnership, Drug development, Imaging, Research, SAN, ISH, Temperature, IHC, Immunohistochemistry, Paradigm

Molecular Instruments®: Inventor of the HCR™ Platform: Molecular Instruments®, the market disruptor in bioimaging and ISH reagents, brings to the table their patented HCR™ Imaging technology.

Key Points: 
  • Molecular Instruments®: Inventor of the HCR™ Platform: Molecular Instruments®, the market disruptor in bioimaging and ISH reagents, brings to the table their patented HCR™ Imaging technology.
  • Biocare Medical's ONCORE Pro X: A Paradigm in Automation: Recognized as a leader in automated instrumentation, Biocare Medical's ONCORE Pro X exemplifies innovation and versatility.
  • Synergizing Strengths for Advanced Bioimaging: The integration of MI's HCR™ Platform into Biocare Medical's ONCORE Pro X instrument represents a synergy of strengths.
  • A New Era in Bioimaging: By integrating Biocare Medical's advanced automated instrumentation with the revolutionary HCR™ Platform from Molecular Instruments, researchers can now harness the power of the ONCORE Pro.

Cancers Journal Publishes Special Issue Dedicated to OGM’s Impact on Hematological Malignancy Research

Retrieved on: 
Thursday, December 14, 2023
Editorial, Oncology, In situ hybridization, CMA, OGM, SVS, Radboud University Medical Center, Research, Workflow, Fluorescence, DRS, Bone marrow, SAN, Doctor of Philosophy, Chronic lymphocytic leukemia, Multiple myeloma, Genomics, University, Karyotype, CLL, Cytogenetics, FACMG, Growth, University of Toronto, Publication, Acute myeloid leukemia, KT, AML, FISH

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow.

Key Points: 
  • SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow.
  • “I personally believe the importance of OGM for hematological malignancies research cannot be overstated.
  • The papers published in this dedicated issue elegantly illustrate how information provided by OGM surpasses the capabilities of the current tools in cancer research.
  • “This special edition of Cancers dedicated to OGM is a significant milestone for the technique and for people in the various fields of genome analysis who are looking for ways to move the community forward.

Biocare Medical Unveils intelliPATH+: Next-Generation Enhancement of the Proven intelliPATH FLX Staining System

Retrieved on: 
Tuesday, December 5, 2023
In situ hybridization, Immunohistochemistry, Workflow, Research, SAN, ISH, IVD, Temperature, ARC, IHC

SAN FRANCISCO, Dec. 5, 2023 /PRNewswire/ -- Biocare Medical, a leader in immunohistochemistry (IHC) and in situ hybridization (ISH) diagnostics, is proud to introduce the intelliPATH+ Advanced Staining Instrument.

Key Points: 
  • SAN FRANCISCO, Dec. 5, 2023 /PRNewswire/ -- Biocare Medical, a leader in immunohistochemistry (IHC) and in situ hybridization (ISH) diagnostics, is proud to introduce the intelliPATH+ Advanced Staining Instrument.
  • The intelliPATH+ has been meticulously redesigned with input from users and the latest technological advancements to become a fully open system that accommodates continuous random access with immediate STAT capabilities.
  • It offers a seamless workflow with increased speed and superior quality in IHC staining, all while reducing waste.
  • The intelliPATH+ system takes command of every analytical detail in the staining process.

Biocare Medical Announces the Launch of ARC: The New IVD Antigen Retrieval Chamber for Reliable, Precise and Consistent Heat Induced Epitope Retrieval (HIER)

Retrieved on: 
Wednesday, November 15, 2023
Pressure, Immunohistochemistry, Research, SAN, Tissue, ISH, Antigen retrieval, Laboratory, In situ hybridization, ARC, Temperature, IVD, IHC

SAN FRANCISCO, Nov. 15, 2023 /PRNewswire/ -- Biocare Medical, a leading provider in the immunohistochemistry sector, introduces their newest innovation: ARC (Antigen Retrieval Chamber).

Key Points: 
  • SAN FRANCISCO, Nov. 15, 2023 /PRNewswire/ -- Biocare Medical, a leading provider in the immunohistochemistry sector, introduces their newest innovation: ARC (Antigen Retrieval Chamber).
  • The addition of ARC to their automation portfolio advances Biocare Medical's suite of decloaking systems built for consistent, reliable heat-induced epitope retrieval.
  • Tailored for Heat-Induced Epitope Retrieval (HIER) with in vitro diagnostic (IVD) labeling, ARC delivers precision and consistency.
  • Recognizing the need for accurate heat, pressure, and buffer solutions, ARC is vital for reliable immunohistochemistry (IHC) and in situ hybridization (ISH) staining.